Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D3 and RANKL

Bone

Volumn 27, Issue 3, 2000, Pages 409-416

  Neale, S D ^a   Smith, R ^b   Wass, J A H ^b   Athanasou, N A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

1,25 dihydroxyvitamin D3; Bone resorption; Osteoclast differentiation factor; Osteoclast formation; Osteoprotegerin (OPG); Paget's disease

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; CALCITRIOL; COLONY STIMULATING FACTOR 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN PRECURSOR; VITRONECTIN RECEPTOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PROTEIN EXPRESSION;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; BONE RESORPTION; CALCITRIOL; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEITIS DEFORMANS; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, VITRONECTIN;

EID: 0033827136     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00345-8     Document Type: Article

References (36)

1. Athanasou N.A. Cellular biology of bone-resorbing cells. J Bone Jt Surg. 78-A:1996;1096-1112.
2. Beedles K.E., Sharpe P.T., Wagner E.F., Grigoriadis A.E. A putative role for c-Fos in the pathophysiology of Paget's disease. J Bone Miner Res. 14:(Suppl.):1999;S21-S28.
3. Breuil V., Cosman F., Stein L., Horbert W., Nieves J., Shen V., Lindsay R., Dempster D.W. Human osteoclast formation and activity in vitro Effects of alendronate . J Bone Miner Res. 13:1998;1721-1729.
4. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W.J., Dunstan C.R., Hu S., Lacey D.L. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 145:1999;527-538.
5. Demulder A., Takahashi S., Singer F.R., Hosking D.J., Roodman G.D. Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. Endocrinology. 133:1993;1978-1982.
6. Fujikawa Y., Quinn J.M.W., Sabokbar A., McGee J.O'D., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 137:1996;4058-4060.
7. Gordon M.T., Mee A.P., Anderson D.C., Sharpe P.T. Canine bone marrow cultures infected with canine distemper virus An in vitro model of Paget's disease . Bone. 19:(Suppl.):1995;S461-S466.
8. Horton M.A., Lewis D., McNulty K., Pringle J.A., Chambers T.J. Monoclonal antibodies to osteoclastomas (giant cell bone tumors) Definition of osteoclast-specific cellular antigens . Cancer Res. 45:1985;5663-5669.
9. Hoyland J.A., Freemont A.J., Sharpe P.T. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J Bone Miner Res. 9:1994;75-80.
10. Hoyland J.A., Sharpe P.T. Up-regulation of c-Fos proto-oncogene expression in pagetic osteoclasts. J Bone Miner Res. 9:1994;1191-1194.
11. Hughes A.E., Ralston S.H., Marken J., Bell C., MacPherson H., Wallace R.G., van Hul W., Whyte M.P., Nakatsuka K., Hovy L., Anderson D.M. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet. 24:2000;45-48.
12. Hughes D.E., MacDonald B.R., Russell R.G.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 83:1989;1930-1935.
13. Jimi E., Akiyama S., Tsurukai T., Kobayashi K., Takahashi N., Udagawa N., Shima N., Kinosaki M., Yamaguchi K., Morinaga T., Higashio K., Suda T. Osteoclast differentiation factor (ODF) induces fusion, survival and activation of osteoclasts. J Bone Miner Res. 23:(Suppl.):1998;S222.
14. Kanis J.A. Pathophysiology and Treatment of Paget's Disease. 1991;Martin Dunitz, London.
15. Kukita A., Chenu C., McManus L.M., Mundy G.R., Roodman G.D. Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. J Clin Invest. 85:1990;1280-1286.
16. Kurihara N., Reddy S.V., Menaa C., Anderson D., Roodman G.D. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest. 105:2000;607-614.
17. Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
18. Matsuzaki K., Udagawa N., Takahashi N., Yamaguchi K., Yasuda H., Shima N., Morinaga T., Toyama Y., Yabe Y., Higashio K., Suda T. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 246:1998;199-204.
19. Mee A.P. Paramyxoviruses and Paget's disease The affirmative view . Bone. 24:(Suppl.):1999;19S-21S.
20. Mills B.G., Frausto A. Cytokines expressed in multinucleated cells Paget's disease and giant cell tumors versus normal bone . Calcif Tissue Int. 61:1997;16-21.
21. Minkin C. Bone acid phosphatase Tartrate-resistant acid phosphatase as a marker of osteoclast function . Calcif Tissue Int. 34:1982;285-290.
22. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 253:1998;395-400.
23. Natale V.M., Filho W.J., Duarte A.J.S. Cellular immunity aspects in elderly subjects with Paget's disease of bone. Calcif Tissue Int. 60:1997;410-414.
24. Nishikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugai N., Yamamoto M., Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 18:1996;9-14.
25. Quinn J.M.W., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
26. Ralston S.H., Hoey S.A., Gallacher S.J., Adamson B.B., Boyle I.T. Cytokine and growth factor expression in Paget's disease Analysis by reverse-transcription/polymerase chain reaction . Br J Rheumatol. 33:1994;620-625.
27. Reddy S.V., Menaa C., Singer F.R., Demulder A., Roodman G.D. Cell biology of Paget's disease. J Bone Miner Res. 14:(Suppl. 2):1999;3-8.
28. Roodman G.D. Advances in bone biology The osteoclast . Endocrine Rev. 17:1996;308-332.
29. Roodman G.D. Paget's disease and osteoclast biology. Bone. 19:1996;209-212.
30. Roodman G.D., Kurihara N., Ohsaki Y., Kukita T., Hosking D., Demulder A., Singer F.S. Interleukin-6 A potential autocrine/paracrine factor in Paget's disease of bone . J Clin Invest. 89:1992;46-52.
31. Russell R.G.G., Rogers M.J., Frith J.C., Luckman S.P., Coxon F.P., Benford H.L., Croucher P.I., Shipman C., Fleisch H.A. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 14:(Suppl. 2):1999;53-65.
32. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. Osteoprotegerin A novel secreted protein involved in the regulation of bone density . Cell. 89:1997;309-319.
33. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 256:1999;449-455.
34. 2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun. 246:1998;337-341.
35. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., Nakagawa N., Yasuda H., Goto M., Tsuda E., Higashio K., Gillespie M.T., Martin T.J., Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone. 25:1999;517-523.
36. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizukt S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.